Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Utah's cell sheet tissue engineering center.

Kim K, Grainger DW, Okano T.

Regen Ther. 2019 May 10;11:2-4. doi: 10.1016/j.reth.2019.03.003. eCollection 2019 Dec. No abstract available.

2.

Antibiotic-eluting resorbable bone-void filler evaluated in a large animal infection prevention model.

Ferrell Z, Grainger DW, Sinclair KD.

Eur Cell Mater. 2019 Apr 8;37:265-276. doi: 10.22203/eCM.v037a16.

3.

Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments.

Wang Y, Grainger DW.

Adv Drug Deliv Rev. 2019 Mar 18. pii: S0169-409X(19)30039-0. doi: 10.1016/j.addr.2019.03.003. [Epub ahead of print]

PMID:
30898571
4.

A murine ex vivo 3D kidney proximal tubule model predicts clinical drug-induced nephrotoxicity.

Diekjürgen D, Grainger DW.

Arch Toxicol. 2019 May;93(5):1349-1364. doi: 10.1007/s00204-019-02430-9. Epub 2019 Mar 12.

PMID:
30863989
5.

A Trans-Atlantic Perspective on Stagnation in Clinical Translation of Antimicrobial Strategies for the Control of Biomaterial-Implant-Associated Infection.

Busscher HJ, Alt V, van der Mei HC, Fagette PH, Zimmerli W, Moriarty TF, Parvizi J, Schmidmaier G, Raschke MJ, Gehrke T, Bayston R, Baddour LM, Winterton LC, Darouiche RO, Grainger DW.

ACS Biomater Sci Eng. 2019 Feb 11;5(2):402-406. doi: 10.1021/acsbiomaterials.8b01071. Epub 2018 Dec 2. Review.

6.

Recommendations for design and conduct of preclinical in vivo studies of orthopedic device-related infection.

Moriarty TF, Harris LG, Mooney RA, Wenke JC, Riool M, Zaat SAJ, Moter A, Schaer TP, Khanna N, Kuehl R, Alt V, Montali A, Liu J, Zeiter S, Busscher HJ, Grainger DW, Richards RG.

J Orthop Res. 2019 Feb;37(2):271-287. doi: 10.1002/jor.24230. Epub 2019 Feb 21. Review.

PMID:
30667561
7.

Drug transporter expression profiling in a three-dimensional kidney proximal tubule in vitro nephrotoxicity model.

Diekjürgen D, Grainger DW.

Pflugers Arch. 2018 Sep;470(9):1311-1323. doi: 10.1007/s00424-018-2150-z. Epub 2018 May 9.

PMID:
29744639
8.

Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence.

Abou-El-Enein M, Grainger DW, Kili S.

Mol Ther. 2018 May 2;26(5):1172-1176. doi: 10.1016/j.ymthe.2018.04.007. Epub 2018 Apr 21. No abstract available.

9.

Comparing ex vivo and in vitro translocation of silver nanoparticles and ions through human nasal epithelium.

Falconer JL, Alt JA, Grainger DW.

Biomaterials. 2018 Jul;171:97-106. doi: 10.1016/j.biomaterials.2018.04.013. Epub 2018 Apr 14.

PMID:
29684679
10.

Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation.

Fortunato A, Grainger DW, Abou-El-Enein M.

Adv Drug Deliv Rev. 2018 Nov - Dec;136-137:97-104. doi: 10.1016/j.addr.2018.01.017. Epub 2018 Jan 31. Review.

PMID:
29408180
11.

In vivo comparisons of silver nanoparticle and silver ion transport after intranasal delivery in mice.

Falconer JL, Grainger DW.

J Control Release. 2018 Jan 10;269:1-9. doi: 10.1016/j.jconrel.2017.10.018. Epub 2017 Oct 20.

PMID:
29061510
12.

Polysaccharide matrices used in 3D in vitro cell culture systems.

Diekjürgen D, Grainger DW.

Biomaterials. 2017 Oct;141:96-115. doi: 10.1016/j.biomaterials.2017.06.020. Epub 2017 Jun 21. Review.

PMID:
28672214
13.

A resorbable antibiotic eluting bone void filler for periprosthetic joint infection prevention.

Jones Z, Brooks AE, Ferrell Z, Grainger DW, Sinclair KD.

J Biomed Mater Res B Appl Biomater. 2016 Nov;104(8):1632-1642. doi: 10.1002/jbm.b.33513. Epub 2015 Aug 31.

PMID:
26332762
14.

Synthetic Biology: Innovative approaches for pharmaceutics and drug delivery.

Deans TL, Grainger DW, Fussenegger M.

Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):1-2. doi: 10.1016/j.addr.2016.08.013. Epub 2016 Sep 18. No abstract available.

PMID:
27653994
15.

Strategies for Derisking Translational Processes for Biomedical Technologies.

Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW.

Trends Biotechnol. 2017 Feb;35(2):100-108. doi: 10.1016/j.tibtech.2016.07.007. Epub 2016 Aug 5. Review.

PMID:
27499276
16.

Extracellular matrix-based biomaterial scaffolds and the host response.

Aamodt JM, Grainger DW.

Biomaterials. 2016 Apr;86:68-82. doi: 10.1016/j.biomaterials.2016.02.003. Epub 2016 Feb 3. Review.

17.

Live RB51 vaccine lyophilized hydrogel formulations with increased shelf life for practical ballistic delivery.

Falconer JL, Christie RJ, Pollard EJ, Olsen SC, Grainger DW.

Int J Pharm. 2016 Feb 10;498(1-2):187-94. doi: 10.1016/j.ijpharm.2015.12.040. Epub 2015 Dec 15.

PMID:
26705151
18.

The 17th International Symposium on Recent Advances in Drug Delivery, June 14-17, 2015, Salt Lake City, UT, USA. Preface.

Grainger DW, Bae YH.

J Control Release. 2015 Dec 28;220(Pt B):569-70. doi: 10.1016/j.jconrel.2015.11.025. No abstract available.

PMID:
26686491
19.

Nanoparticle Uptake: The Phagocyte Problem.

Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H.

Nano Today. 2015 Aug;10(4):487-510. Epub 2015 Sep 5.

20.

Local release of masitinib alters in vivo implantable continuous glucose sensor performance.

Avula M, Jones D, Rao AN, McClain D, McGill LD, Grainger DW, Solzbacher F.

Biosens Bioelectron. 2016 Mar 15;77:149-56. doi: 10.1016/j.bios.2015.08.059. Epub 2015 Sep 14.

PMID:
26402593
21.

Fat Prospects for Healing Cutaneous Wounds: New Activities Under the Sheets.

Grainger DW.

Diabetes. 2015 Aug;64(8):2717-9. doi: 10.2337/db15-0533. No abstract available.

22.

Wound healing: Enzymatically crosslinked scaffolds.

Grainger DW.

Nat Mater. 2015 Jul;14(7):662-3. doi: 10.1038/nmat4337. No abstract available.

PMID:
26099714
23.

Fracture management in horses: Where have we been and where are we going?

Auer JA, Grainger DW.

Vet J. 2015 Oct;206(1):5-14. doi: 10.1016/j.tvjl.2015.06.002. Epub 2015 Jun 4. No abstract available.

PMID:
26095036
24.

Novel xeno-free human heart matrix-derived three-dimensional scaffolds.

Holt-Casper D, Theisen JM, Moreno AP, Warren M, Silva F, Grainger DW, Bull DA, Patel AN.

J Transl Med. 2015 Jun 18;13:194. doi: 10.1186/s12967-015-0559-0.

25.

Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations.

Hofmann-Amtenbrink M, Grainger DW, Hofmann H.

Nanomedicine. 2015 Oct;11(7):1689-94. doi: 10.1016/j.nano.2015.05.005. Epub 2015 Jun 4. Review.

PMID:
26051651
26.

Key elements for nourishing the translational research environment.

Volk HD, Stevens MM, Mooney DJ, Grainger DW, Duda GN.

Sci Transl Med. 2015 Apr 8;7(282):282cm2. doi: 10.1126/scitranslmed.aaa2049.

27.

A resorbable antibiotic-eluting polymer composite bone void filler for perioperative infection prevention in a rabbit radial defect model.

Brooks BD, Sinclair KD, Grainger DW, Brooks AE.

PLoS One. 2015 Mar 27;10(3):e0118696. doi: 10.1371/journal.pone.0118696. eCollection 2015.

28.

Extended culture of macrophages from different sources and maturation results in a common M2 phenotype.

Chamberlain LM, Holt-Casper D, Gonzalez-Juarrero M, Grainger DW.

J Biomed Mater Res A. 2015 Sep;103(9):2864-74. doi: 10.1002/jbm.a.35415. Epub 2015 Feb 27.

29.

'Erratum to "Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines" [Biomaterials 33 (2012) 4712-4721]'.

Astashkina AI, Mann BK, Prestwich GD, Grainger DW.

Biomaterials. 2015 Jan;38:108. doi: 10.1016/j.biomaterials.2014.10.072. Epub 2014 Nov 11. No abstract available.

PMID:
25499931
30.

Changing the mindset in life sciences toward translation: a consensus.

Duda GN, Grainger DW, Frisk ML, Bruckner-Tuderman L, Carr A, Dirnagl U, Einhäupl KM, Gottschalk S, Gruskin E, Huber C, June CH, Mooney DJ, Rietschel ET, Schütte G, Seeger W, Stevens MM, Urban R, Veldman A, Wess G, Volk HD.

Sci Transl Med. 2014 Nov 26;6(264):264cm12. doi: 10.1126/scitranslmed.aaa0599.

PMID:
25429054
31.

Polymer-controlled extended combination release of silver and chlorhexidine from a bone void filler.

Degooyer J, Davidoff SN, Brooks BD, Grainger DW, Brooks AE.

Biomed Sci Instrum. 2014;50:47-53.

PMID:
25405403
32.

Challenges in linking preclinical anti-microbial research strategies with clinical outcomes for device-associated infections.

Moriarty TF, Grainger DW, Richards RG.

Eur Cell Mater. 2014 Sep 12;28:112-28; discussion 128. Review.

33.

Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model.

Astashkina AI, Jones CF, Thiagarajan G, Kurtzeborn K, Ghandehari H, Brooks BD, Grainger DW.

Biomaterials. 2014 Aug;35(24):6323-31. doi: 10.1016/j.biomaterials.2014.04.060. Epub 2014 May 10.

PMID:
24814424
34.
35.

Cell-based drug testing; this world is not flat.

Grainger DW.

Adv Drug Deliv Rev. 2014 Apr;69-70:vii-xi. doi: 10.1016/j.addr.2014.04.001. Epub 2014 Apr 4. No abstract available.

PMID:
24709443
36.

A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs.

Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, Jin Y, Yu L, Grainger DW, Ying W.

Int J Med Sci. 2014 Mar 18;11(5):479-87. doi: 10.7150/ijms.8340. eCollection 2014.

37.

Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments.

Astashkina A, Grainger DW.

Adv Drug Deliv Rev. 2014 Apr;69-70:1-18. doi: 10.1016/j.addr.2014.02.008. Epub 2014 Mar 5. Review.

PMID:
24613390
38.

A critical comparison of protein microarray fabrication technologies.

Romanov V, Davidoff SN, Miles AR, Grainger DW, Gale BK, Brooks BD.

Analyst. 2014 Mar 21;139(6):1303-26. doi: 10.1039/c3an01577g. Review.

PMID:
24479125
39.

Metabolically active human brown adipose tissue derived stem cells.

Silva FJ, Holt DJ, Vargas V, Yockman J, Boudina S, Atkinson D, Grainger DW, Revelo MP, Sherman W, Bull DA, Patel AN.

Stem Cells. 2014 Feb;32(2):572-81. doi: 10.1002/stem.1595.

40.

Foreign body response to subcutaneous biomaterial implants in a mast cell-deficient Kit(w-Sh) murine model.

Avula MN, Rao AN, McGill LD, Grainger DW, Solzbacher F.

Acta Biomater. 2014 May;10(5):1856-63. doi: 10.1016/j.actbio.2013.12.056. Epub 2014 Jan 7.

PMID:
24406200
41.

Molded polymer-coated composite bone void filler improves tobramycin controlled release kinetics.

Brooks BD, Sinclair KD, Davidoff SN, Lawson S, Williams AG, Coats B, Grainger DW, Brooks AE.

J Biomed Mater Res B Appl Biomater. 2014 Jul;102(5):1074-83. doi: 10.1002/jbm.b.33089. Epub 2013 Dec 26.

PMID:
24376164
42.

Polymer-controlled release of tobramycin from bone graft void filler.

Brooks AE, Brooks BD, Davidoff SN, Hogrebe PC, Fisher MA, Grainger DW.

Drug Deliv Transl Res. 2013 Dec;3(6):518-30. doi: 10.1007/s13346-013-0155-x.

PMID:
25786372
43.

Developing siRNA therapies to address osteoporosis.

Wang Y, Grainger DW.

Ther Deliv. 2013 Oct;4(10):1239-46. doi: 10.4155/tde.13.85. Review.

44.

Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib.

Avula MN, Rao AN, McGill LD, Grainger DW, Solzbacher F.

Biomaterials. 2013 Dec;34(38):9737-46. doi: 10.1016/j.biomaterials.2013.08.090. Epub 2013 Sep 20.

PMID:
24060424
45.

Critical factors in the translation of improved antimicrobial strategies for medical implants and devices.

Grainger DW, van der Mei HC, Jutte PC, van den Dungen JJ, Schultz MJ, van der Laan BF, Zaat SA, Busscher HJ.

Biomaterials. 2013 Dec;34(37):9237-43. doi: 10.1016/j.biomaterials.2013.08.043. Epub 2013 Sep 11.

PMID:
24034505
46.

The 16th International Symposium on Recent Advances in Drug Delivery, February 3-6, 2013, Salt Lake City, UT, USA.

Bae YH, Grainger DW.

J Control Release. 2013 Dec 10;172(2):393-4. doi: 10.1016/j.jconrel.2013.08.003. Epub 2013 Aug 8. No abstract available.

PMID:
23933521
47.

In vivo human time-exposure study of orally dosed commercial silver nanoparticles.

Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE.

Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28.

48.

All charged up about implanted biomaterials.

Grainger DW.

Nat Biotechnol. 2013 Jun;31(6):507-9. doi: 10.1038/nbt.2600. No abstract available.

PMID:
23752436
49.
50.

Connecting drug delivery reality to smart materials design.

Grainger DW.

Int J Pharm. 2013 Sep 15;454(1):521-4. doi: 10.1016/j.ijpharm.2013.04.061. Epub 2013 Apr 24.

PMID:
23624177

Supplemental Content

Loading ...
Support Center